DOCSLIB.ORG

Loss-Of-Function Mutations in Notch Receptors in Cutaneous and Lung Squamous Cell Carcinoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Loss-Of-Function Mutations in Notch Receptors in Cutaneous and Lung Squamous Cell Carcinoma Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma Nicholas J. Wanga,1, Zachary Sanbornb,1, Kelly L. Arnettc, Laura J. Baystonc, Wilson Liaod, Charlotte M. Probye, Irene M. Leighe, Eric A. Collissonf, Patricia B. Gordong, Lakshmi Jakkulaa, Sally Pennypackerd, Yong Zouh, Mimansa Sharmai, Jeffrey P. Northi, Swapna S. Vemulaj, Theodora M. Maurod, Isaac M. Neuhausd, Philip E. LeBoitj, Joe S. Hurk, Kyunghee Parkl, Nam Huhl, Pui-Yan Kwokd, Sarah T. Arrond, Pierre P. Massionh, Allen E. Baleg, David Hausslerb, James E. Cleaverd,2, Joe W. Graym, Paul T. Spellmann, Andrew P. Southe, Jon C. Asterc,3, Stephen C. Blacklowc,o,p,3, and Raymond J. Chod,2,3 aLife Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720; bCenter for Biomolecular Science and Engineering, University of California, Santa Cruz, CA 95064; cDepartment of Pathology, Brigham and Women’s Hospital, Boston, MA 02115; Departments of dDermatology, fHematology and Oncology, and iPathology, University of California, San Francisco, CA 94143; eDivision of Cancer Research, Medical Research Institute, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom; gDepartment of Genetics, Yale University, CT 06520; hDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University, TN 37232; jUniversity of California, San Francisco Dermatopathology Service, San Francisco, CA 94115; kSamsung Electronics Headquarters, Seocho-gu, Seoul 137-857, Korea; lEmerging Technology Research Center, Samsung Advanced Institute of Technology, Kyunggi-do 446-712, Korea; Departments of mBiomedical Engineering and nMolecular and Medical Genetics, Oregon Health Sciences University, Portland OR 97239; oDepartment of Cancer Biology, Dana–Farber Cancer Institute, and pDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115 Contributed by James E. Cleaver, September 12, 2011 (sent for review August 1, 2011) Squamous cell carcinomas (SCCs) are one of the most frequent than 10% of head and neck SCCs and cSCCs carry EGFR and forms of human malignancy, but, other than TP53 mutations, few PIK3CA gain-of-function mutations (7–9), and the oncogenic causative somatic aberrations have been identified. We identified kinase DDR2 is activated in ∼5% of lung SCC primary tumors NOTCH1 or NOTCH2 mutations in ∼75% of cutaneous SCCs and and cell lines (10). In fact, most SCCs lack an identifiable clas- in a lesser fraction of lung SCCs, defining a spectrum for the most sical driver mutation, stalling deployment of targeted treatments. prevalent tumor suppressor specific to these epithelial malignan- Although virtually all SCCs harbor TP53 mutations, additional cies. Notch receptors normally transduce signals in response to tumor suppressors have proved elusive. Recent studies have ligands on neighboring cells, regulating metazoan lineage selec- implicated loss of function in NOTCH1, IRF6, and TP53 in head fi tion and developmental patterning. Our ndings therefore illus- and neck SCCs (11, 12). Several models suggest that inactivation trate a central role for disruption of microenvironmental com- of Smad proteins up-regulates TGF signaling, but somatic mu- NOTCH munication in cancer progression. aberrations include tations have not been detected in primary cancers (13). frameshift and nonsense mutations leading to receptor trunca- We recently integrated whole-exome DNA sequence and al- tions as well as point substitutions in key functional domains that lele-specific copy number data to examine somatically acquired abrogate signaling in cell-based assays. Oncogenic gain-of-func- genomic aberrations in eight primary cSCCs (14). Given the very tion mutations in NOTCH1 commonly occur in human T-cell lym- high mutation burdens in these cancers, we sought to increase phoblastic leukemia/lymphoma and B-cell chronic lymphocytic specificity for genes with a causative role in tumorigenesis. A leukemia. The bifunctional role of Notch in human cancer thus emphasizes the context dependency of signaling outcomes and search for mutations accompanied by loss of the wild-type allele—a pattern shared by known tumor suppressors in our se- suggests that targeted inhibition of the Notch pathway may in- TP53 CDKN2A— fi duce squamous epithelial malignancies. ries, including and identi ed multiple muta- tions in Notch receptors. cancer genetics | genomic | cellular signaling Notch receptors participate in a highly conserved signal trans- duction pathway that regulates many aspects of development through context-dependent effects on cell fate determination (15, quamous cell carcinomas (SCCs) collectively are the most 16), growth (17), and survival (18). Cognate ligands expressed on common ectodermal cancers, resulting in >300,000 deaths S the surface of signal-sending cells bind the EGF-like repeats of per year (1, 2). SCCs arise from renewable squamous epithelial the Notch ectodomain on signal-receiving cells, initiating a series cells that serve to create an environmental barrier in the skin, of proteolytic cleavage events that allow the Notch intracellular esophagus, lung, and cervix. In normal squamous epithelia, basal domain (NICD) to translocate to the nucleus and form a tran- progenitors give rise to more superficial daughter cells that ter- MEDICAL SCIENCES minally differentiate into keratinized cells as they migrate toward the surface, coupling terminal differentiation with microanatomic Author contributions: N.J.W., Z.S., K.L.A., W.L., C.M.P., I.M.L., E.A.C., P.B.G., Y.Z., M.S., J.P.N., position. An early feature of squamous neoplasia of all types is S.S.V., T.M.M., I.M.N., P.E.L., J.S.H., K.P., N.H., P.-Y.K., S.T.A., P.P.M., A.E.B., J.E.C., P.T.S., disrupted differentiation to variable degrees, typically associated A.P.S., J.C.A., S.C.B., and R.J.C. designed research; N.J.W., Z.S., K.L.A., L.J.B., W.L., C.M.P., with thickening of the epithelium and increased proliferation. L.J., and R.J.C. performed research; K.P., N.H., D.H., and J.W.G. contributed new reagents/ Therefore, although SCCs from different sites demonstrate vary- analytic tools; N.J.W., Z.S., K.L.A., W.L., C.M.P., I.M.L., E.A.C., P.B.G., Y.Z., M.S., J.P.N., — S.S.V., T.M.M., I.M.N., P.E.L., J.S.H., K.P., P.-Y.K., S.T.A., P.P.M., A.E.B., D.H., P.T.S., J.C.A., ing epidemiologic associations UV radiation in skin cancers, S.C.B., and R.J.C. analyzed data; and N.J.W., P.B.G., S.P., M.S., J.P.N., T.M.M., J.E.C., A.P.S., alcohol and tobacco exposure in esophageal cancers, and human J.C.A., S.C.B., and R.J.C. wrote the paper. papillomavirus infection in cervical and head and neck cancers— The authors declare no conflict of interest. they likely share disruption of pathways that coordinate micro- Freely available online through the PNAS open access option. environment-dependent squamous differentiation (3). 1N.J.W. and Z.S. contributed equally to this work. Although emerging targeted therapies show promise in epi- 2To whom correspondence may be addressed. E-mail: [email protected] or chorj@ thelial cancers, few recurrent genetic aberrations have been derm.ucsf.edu. identified in lung SCCs or cutaneous SCCs (cSCCs) (4). Acti- 3J.C.A., S.C.B., and R.J.C. contributed equally to this work. HRAS vating mutations are highly prevalent in murine SCC-like This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. malignancies but rare in their human counterparts (5, 6). Fewer 1073/pnas.1114669108/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1114669108 PNAS | October 25, 2011 | vol. 108 | no. 43 | 17761–17766 Downloaded by guest on October 2, 2021 scription activation complex with the DNA binding factor RBPJ NOTCH1 or NOTCH2 (Table S1). No association with clinical (also known as CSL) and coactivators of the Mastermind-like subtype or TP53 status was noted (Table S2). (MAML) family (19). Although activating mutations in Notch1 Recent exome-sequencing data from 40 lung SCCs acquired occur in the majority of T-cell lymphoblastic leukemia/lym- by The Cancer Genome Atlas (TCGA) project were also ex- phoma (20) and are also often present in poor-prognosis B-cell amined. Three missense mutations and one splice site mutation chronic lymphocytic leukemia (21–23), loss of Notch activity can were identified in NOTCH1, as well as one missense and one also produce basal cell carcinoma-like cancers (24) or squamous nonsense mutation in NOTCH2—a combined mutation fre- cancers (25) in mice, suggesting that the consequence of specific quency of 5/40 samples or 12.5% (Table S1). Sanger sequencing somatic Notch aberrations in cancer is strongly influenced by for NOTCH1 and NOTCH2 in lung SCC cell lines SW900 and epigenetic context. Current models propose that Notch tran- HCC95, esophageal SCC lines TT and TE10, and lung adeno- scriptional down-regulation, possibly due to loss of p53 function, carcinoma lines H549 and A549 revealed a single heterozygous is a causative event in human epithelial malignancies (26), but nonsense NOTCH1 mutation in TE10. disabling somatic aberrations have not been reported in cSCCs or lung SCCs. Here, we describe and functionally characterize Analysis of Unique Notch1 Loss-of-Function Mutants. Amino acid frequent Notch loss-of-function mutations in these malignancies. (missense) changes were analyzed by PolyPhen-2 (http://genetics. bwh.harvard.edu/pph2/) for potential structural effects. Eighteen Results of 27 mutations were identified as “probably damaging” with Identification of Notch Mutations. Three additional cSCCs were the remainder being labeled “probably benign” (Table S3). Be- sequenced on the whole-exome level, in addition to the eight sides overt loss-of-function frameshift and nonsense mutations, originally reported (14).
Load more

Recommended publications
  • Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms
    Journal of Clinical Medicine Review Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms 1,2, 1, 3, 4 Claudia von Arx y , Monica Capozzi y, Elena López-Jiménez y, Alessandro Ottaiano , Fabiana Tatangelo 5 , Annabella Di Mauro 5, Guglielmo Nasti 4, Maria Lina Tornesello 6,* and Salvatore Tafuto 1,* On behalf of ENETs (European NeuroEndocrine Tumor Society) Center of Excellence of Naples, Italy 1 Department of Abdominal Oncology, Istituto Nazionale Tumori, IRCCS Fondazione “G. Pascale”, 80131 Naples, Italy 2 Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK 3 Cancer Cell Metabolism Group. Centre for Haematology, Immunology and Inflammation Department, Imperial College London, London W12 0HS, UK 4 SSD Innovative Therapies for Abdominal Metastases—Department of Abdominal Oncology, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy 5 Department of Pathology, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy 6 Unit of Molecular Biology and Viral Oncology, Department of Research, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy * Correspondence: [email protected] (M.L.T.); [email protected] (S.T.) These authors contributed to this paper equally. y Received: 10 July 2019; Accepted: 20 August 2019; Published: 22 August 2019 Abstract: Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of rare malignancies, mainly originating from hormone-secreting cells, which are widespread in human tissues. The identification of mutations in ATRX/DAXX genes in sporadic NENs, as well as the high burden of mutations scattered throughout the multiple endocrine neoplasia type 1 (MEN-1) gene in both sporadic and inherited syndromes, provided new insights into the molecular biology of tumour development.
    [Show full text]
  • Spatial Regulation and Generation of Diversity in Signaling Pathways
    J Biosci (2021)46:30 Ó Indian Academy of Sciences DOI: 10.1007/s12038-021-00150-w (0123456789().,-volV)(0123456789().,-volV) Review Spatial regulation and generation of diversity in signaling pathways 1,2 1 NEETU SAINI and APURVA SARIN * 1Institute for Stem Cell Science and Regenerative Medicine, Bellary Road, Bengaluru 560 065, India 2Department of Biology, Manipal Academy of Higher Education, Manipal, India *Corresponding author (Email, [email protected]) MS received 9 November 2020; accepted 19 February 2021 Signaling pathways orchestrate diverse cellular outcomes in the same tissue, spatially and temporally. These interactions, which are played out in micro-environments within cells and involve a relatively small number of core pathways, are the key to the development and function of multi-cellular organisms. How these outcomes are regulated has prompted interest in intracellular mechanisms that build diversity in signaling outcomes. This review specifically addresses spatial positioning of molecules as a means of enabling interactions and novel outcomes of signaling cascades. Using the Notch and Ras pathways as exemplars, we describe mechanisms that contribute to diverse signaling outcomes. Keywords. Cross-talk; notch; signaling; spatial regulation 1. Introduction and Blair 1999; Baonza and Garcia-Bellido 2000; Becam et al. 2011), and in the lymph gland, the dif- Cell-to-cell communication is critical for the develop- ferentiation and survival of crystal cells (Duvic et al. ment and maintenance of multi-cellular organisms. 2002). In the PC12 neuronal cell line, activation of Development or repair following injury, requires receptor tyrosine kinase (RTK) in response to nerve interactions between many cell types for specific of cell growth factor (NGF) and epidermal growth factor fates, and breakdown or errors in these can lead to (EGF) regulates differentiation and proliferation various disorders or pathophysiological conditions respectively.
    [Show full text]
  • Tyrosine Phosphorylation and Proteolytic Cleavage of Notch Are
    © 2018. Published by The Company of Biologists Ltd | Development (2018) 145, dev151548. doi:10.1242/dev.151548 RESEARCH ARTICLE Tyrosine phosphorylation and proteolytic cleavage of Notch are required for non-canonical Notch/Abl signaling in Drosophila axon guidance Ramakrishnan Kannan1,*, Eric Cox1,‡, Lei Wang2,§, Irina Kuzina1,QunGu1 and Edward Giniger1,2,¶ ABSTRACT 2005) and the Akt pathway (Androutsellis-Theotokis et al., 2006; Notch signaling is required for the development and physiology of Perumalsamy et al., 2009), among others, that extend the menu of nearly every tissue in metazoans. Much of Notch signaling is molecular outcomes of Notch activation. The molecular events mediated by transcriptional regulation of downstream target genes, behind these alternative signaling mechanisms, however, are not well but Notch controls axon patterning in Drosophila by local modulation understood. of Abl tyrosine kinase signaling, via direct interactions with the Abl co- Perhaps the best-studied non-traditional function of Notch is its factors Disabled and Trio. Here, we show that Notch-Abl axonal regulation of axon patterning (comprising both axon growth and signaling requires both of the proteolytic cleavage events that initiate axon guidance) via interaction with the Abl tyrosine kinase canonical Notch signaling. We further show that some Notch protein signaling network (Crowner et al., 2003; Giniger, 1998; Kuzina is tyrosine phosphorylated in Drosophila, that this form of the protein et al., 2011; Le Gall et al., 2008). It has been demonstrated is selectively associated with Disabled and Trio, and that relevant biochemically, molecularly and genetically that, upon activation by tyrosines are essential for Notch-dependent axon patterning but not its ligand Delta, Notch promotes the growth and guidance of pioneer for canonical Notch-dependent regulation of cell fate.
    [Show full text]
  • It's T-ALL About Notch
    Oncogene (2008) 27, 5082–5091 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $30.00 www.nature.com/onc REVIEW It’s T-ALL about Notch RM Demarest1, F Ratti1 and AJ Capobianco Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA T-cell acute lymphoblastic leukemia (T-ALL) is an about T-ALL make it a more aggressive disease with a aggressive subset ofALL with poor clinical outcome poorer clinical outcome than B-ALL. T-ALL patients compared to B-ALL. Therefore, to improve treatment, it have a higher percentage of induction failure, and rate is imperative to delineate the molecular blueprint ofthis of relapse and invasion into the central nervous system disease. This review describes the central role that the (reviewed in Aifantis et al., 2008). The challenge to Notch pathway plays in T-ALL development. We also acquiring 100% remission in T-ALL treatment is the discuss the interactions between Notch and the tumor subset of patients (20–25%) whose disease is refractory suppressors Ikaros and p53. Loss ofIkaros, a direct to initial treatments or relapses after a short remission repressor ofNotch target genes, and suppression ofp53- period due to drug resistance. Therefore, it is imperative mediated apoptosis are essential for development of this to delineate the molecular blueprint that collectively neoplasm. In addition to the activating mutations of accounts for the variety of subtypes in T-ALL. This will Notch previously described, this review will outline allow for the development of targeted therapies that combinations ofmutations in pathways that contribute inhibit T-ALL growth by disrupting the critical path- to Notch signaling and appear to drive T-ALL develop- ways responsible for the neoplasm.
    [Show full text]
  • Suppression of Notch Signaling Stimulates Progesterone Synthesis by Enhancing the Expression of NR5A2 and NR2F2 in Porcine Granulosa Cells
    G C A T T A C G G C A T genes Article Suppression of Notch Signaling Stimulates Progesterone Synthesis by Enhancing the Expression of NR5A2 and NR2F2 in Porcine Granulosa Cells Rihong Guo 1,2, Fang Chen 2 and Zhendan Shi 1,2,* 1 Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, China; [email protected] 2 Institute of Animal Science, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, China; [email protected] * Correspondence: [email protected] Received: 16 December 2019; Accepted: 18 January 2020; Published: 22 January 2020 Abstract: The conserved Notch pathway is reported to be involved in progesterone synthesis and secretion; however, the exact effects remain controversial. To determine the role and potential mechanisms of the Notch signaling pathway in progesterone biosynthesis in porcine granulosa cells (pGCs), we first used a pharmacological γ-secretase inhibitor, N-(N-(3,5-difluorophenacetyl-l-alanyl))-S-phenylglycine t-butyl ester (DAPT), to block the Notch pathway in cultured pGCs and then evaluated the expression of genes in the progesterone biosynthesis pathway and key transcription factors (TFs) regulating steroidogenesis. We found that DAPT dose- and time-dependently increased progesterone secretion. The expression of steroidogenic proteins NPC1 and StAR and two TFs, NR5A2 and NR2F2, was significantly upregulated, while the expression of HSD3B was significantly downregulated. Furthermore, knockdown of both NR5A2 and NR2F2 with specific siRNAs blocked the upregulatory effects of DAPT on progesterone secretion and reversed the effects of DAPT on the expression of NPC1, StAR, and HSD3B.
    [Show full text]
  • MAML1 Antibody A
    Revision 1 C 0 2 - t MAML1 Antibody a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 8 0 Web: [email protected] 6 www.cellsignal.com 4 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB, IP H Endogenous 130 Rabbit Q92585 9794 Product Usage Information Application Dilution Western Blotting 1:1000 Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity MAML1 Antibody detects endogenous levels of total MAML1 protein. It does not cross- react with MAML2 and MAML3. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His811 of human MAML1. Antibodies are purified by protein A and peptide affinity chromatography. Background Mastermind-like (MAML) family of proteins are homologs of Drosophila Mastermind. The family is composed of three members in mammals: MAML1, MAML2, and MAML3 (1,2). MAML proteins form complexes with the intracellular domain of Notch (ICN) and the transcription factor CSL (RBP-Jκ) to regulate Notch target gene expression (3-5). MAML1 also interacts with myocyte enhancer factor 2C (MEF2C) to regulate myogenesis (6). MAML2 is frequently found to be fused with Mucoepidermoid carcinoma translocated gene 1 (MECT1, also know as WAMTP1 or TORC1) in patients with mucoepidermoid carcinomas and Warthin's tumors (7).
    [Show full text]
  • Coactivation of NF-Kb and Notch Signaling Is Sufficient to Induce B
    Regular Article LYMPHOID NEOPLASIA Coactivation of NF-kB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion Downloaded from https://ashpublications.org/blood/article-pdf/135/2/108/1550992/bloodbld2019001438.pdf by UNIV OF IOWA LIBRARIES user on 20 February 2020 Yan Xiu,1,* Qianze Dong,1,2,* Lin Fu,1,2 Aaron Bossler,1 Xiaobing Tang,1,2 Brendan Boyce,3 Nicholas Borcherding,1 Mariah Leidinger,1 Jose´ Luis Sardina,4,5 Hai-hui Xue,6 Qingchang Li,2 Andrew Feldman,7 Iannis Aifantis,8 Francesco Boccalatte,8 Lili Wang,9 Meiling Jin,9 Joseph Khoury,10 Wei Wang,10 Shimin Hu,10 Youzhong Yuan,11 Endi Wang,12 Ji Yuan,13 Siegfried Janz,14 John Colgan,15 Hasem Habelhah,1 Thomas Waldschmidt,1 Markus Muschen,¨ 9 Adam Bagg,16 Benjamin Darbro,17 and Chen Zhao1,18 1Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA; 2Department of Pathology, China Medical University, Shenyang, China; 3Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY; 4Gene Regulation, Stem Cells and Cancer Program, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain; 5Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol, Barcelona, Spain; 6Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA; 7Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN; 8Department of Pathology, NYU School of Medicine,
    [Show full text]
  • Notch Signaling: Simplicity in Design, Versatility in Function Emma R
    REVIEW 3593 Development 138, 3593-3612 (2011) doi:10.1242/dev.063610 © 2011. Published by The Company of Biologists Ltd Notch signaling: simplicity in design, versatility in function Emma R. Andersson1, Rickard Sandberg2 and Urban Lendahl1,* Summary different cell types and organs have recently been reviewed (Liu et Notch signaling is evolutionarily conserved and operates in al., 2010) and are summarized in Table 1. In keeping with its many cell types and at various stages during development. important role in many cell types, the mutation of Notch genes Notch signaling must therefore be able to generate leads to diseases in various organs and tissues (Table 2). These appropriate signaling outputs in a variety of cellular contexts. studies highlight the fact that the Notch pathway must be able to This need for versatility in Notch signaling is in apparent elicit appropriate responses in many spatially and temporally contrast to the simple molecular design of the core pathway. distinct cell contexts. Here, we review recent studies in nematodes, Drosophila and In this review, we address the conundrum of how this functional vertebrate systems that begin to shed light on how versatility diversity is compatible with the simplistic molecular design of the in Notch signaling output is generated, how signal strength is Notch signaling pathway. In particular, we focus on recent modulated, and how cross-talk between the Notch pathway observations, in both vertebrate and invertebrate systems, that and other intracellular signaling systems, such as the Wnt, begin to shed light on how diversity is generated at different steps hypoxia and BMP pathways, contributes to signaling diversity.
    [Show full text]
  • NOTCH1 Gene Notch 1
    NOTCH1 gene notch 1 Normal Function The NOTCH1 gene provides instructions for making a protein called Notch1, a member of the Notch family of receptors. Receptor proteins have specific sites into which certain other proteins, called ligands, fit like keys into locks. Attachment of a ligand to the Notch1 receptor sends signals that are important for normal development of many tissues throughout the body, both before birth and after. Notch1 signaling helps determine the specialization of cells into certain cell types that perform particular functions in the body (cell fate determination). It also plays a role in cell growth and division (proliferation), maturation (differentiation), and self-destruction (apoptosis). The protein produced from the NOTCH1 gene has such diverse functions that the gene is considered both an oncogene and a tumor suppressor. Oncogenes typically promote cell proliferation or survival, and when mutated, they have the potential to cause normal cells to become cancerous. In contrast, tumor suppressors keep cells from growing and dividing too fast or in an uncontrolled way, preventing the development of cancer; mutations that impair tumor suppressors can lead to cancer development. Health Conditions Related to Genetic Changes Adams-Oliver syndrome At least 15 mutations in the NOTCH1 gene have been found to cause Adams-Oliver syndrome, a condition characterized by areas of missing skin (aplasia cutis congenita), usually on the scalp, and malformations of the hands and feet. These mutations are usually inherited and are present in every cell of the body. Some of the NOTCH1 gene mutations involved in Adams-Oliver syndrome lead to production of an abnormally short protein that is likely broken down quickly, causing a shortage of Notch1.
    [Show full text]
  • Notch Signaling in Breast Cancer: a Role in Drug Resistance
    cells Review Notch Signaling in Breast Cancer: A Role in Drug Resistance McKenna BeLow 1 and Clodia Osipo 1,2,3,* 1 Integrated Cell Biology Program, Loyola University Chicago, Maywood, IL 60513, USA; [email protected] 2 Department of Cancer Biology, Loyola University Chicago, Maywood, IL 60513, USA 3 Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL 60513, USA * Correspondence: [email protected]; Tel.: +1-708-327-2372 Received: 12 September 2020; Accepted: 28 September 2020; Published: 29 September 2020 Abstract: Breast cancer is a heterogeneous disease that can be subdivided into unique molecular subtypes based on protein expression of the Estrogen Receptor, Progesterone Receptor, and/or the Human Epidermal Growth Factor Receptor 2. Therapeutic approaches are designed to inhibit these overexpressed receptors either by endocrine therapy, targeted therapies, or combinations with cytotoxic chemotherapy. However, a significant percentage of breast cancers are inherently resistant or acquire resistance to therapies, and mechanisms that promote resistance remain poorly understood. Notch signaling is an evolutionarily conserved signaling pathway that regulates cell fate, including survival and self-renewal of stem cells, proliferation, or differentiation. Deregulation of Notch signaling promotes resistance to targeted or cytotoxic therapies by enriching of a small population of resistant cells, referred to as breast cancer stem cells, within the bulk tumor; enhancing stem-like features during the process of de-differentiation of tumor cells; or promoting epithelial to mesenchymal transition. Preclinical studies have shown that targeting the Notch pathway can prevent or reverse resistance through reduction or elimination of breast cancer stem cells. However, Notch inhibitors have yet to be clinically approved for the treatment of breast cancer, mainly due to dose-limiting gastrointestinal toxicity.
    [Show full text]
  • 3641 Molecular and Other Predictors for Infertility in Patients with Va
    [Frontiers in Bioscience 14, 3641-3672, January 1, 2009] Molecular and other predictors for infertility in patients with varicoceles Susan Benoff1,2,3,5, Joel L. Marmar4, Ian R. Hurley1 1Fertility Research Laboratories, Center for Oncology and Cell Biology, The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, New York, 2Department of Obstetrics and Gynecology, North Shore University Hospital, Manhasset, New York, 3Departments of Obstetrics and Gynecology and Cell Biology, New York University School of Medicine, New York, New York, 4Department of Urology, Robert Wood Johnson School of Medicine, Camden, New Jersey, 5350 Community Drive, Room 125, Manhasset, New York 11030 TABLE OF CONTENTS 1. Abstract 2. Definition 3. Frequency of occurrence and presentation 3.1. Association with infertility and current treatment 4. The varicocele controversy 5. Potential mechanisms 6. Deficits already identified 6.1. Scrotal/testicular hyperthermia 6.2. Increased venous pressures 6.3. Accumulation of toxic substances 6.3.1 Intrinsic toxins 6.3.2. Extrinsic toxins 6.4. Hypoxia 6.5. Hormonal imbalance 6.6. Additional molecular changes 7. Use of animal models 7.1. Experimental left varicocele 7.1.1. Recapitulation of effects observed in human males with varicoceles 7.1.2. Additional changes not yet reported in human subjects 7.2. Elevated temperature 7.3. Effect of toxins 7.3.1. A potential role for genetics in sensitivity or resistance to cadmium-induced testicular damage 7.4. Androgen deprivation 8. Medical therapies 8.1. Oxidative stress 8.1.1. Antioxidants 8.1.2. Supplementary zinc 8.1.3. Anti-inflammatory drugs 8.2.
    [Show full text]
  • Notch-Jagged Signaling Complex Defined by an Interaction Mosaic
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.19.432005; this version posted February 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Research Article Notch-Jagged signaling complex defined by an interaction mosaic Matthieu R. Zeronian1,4, Oleg Klykov2,3,4,5,Julia´ Portell i de Montserrat1,6, Maria J. Konijnenberg1, Anamika Gaur1,7, Richard A. Scheltema2,3* Bert J.C. Janssen1* Abstract The Notch signaling system links cellular fate to that of its neighbors, driving proliferation, apoptosis, and cell differentiation in metazoans, whereas dysfunction leads to debilitating developmental disorders and cancers. Other than a five-by-five domain complex, it is unclear how the 40 extracellular domains of the Notch1 receptor collectively engage the 19 domains of its canonical ligand Jagged1 to activate Notch1 signaling. Here, using cross-linking mass spectrometry (XL-MS), biophysical and structural techniques on the full extracellular complex and targeted sites,we identify five distinct regions, two on Notch1 and three on Jagged1, that form an interaction network.The Notch1 membrane-proximal regulatory region individually binds to the established Notch1 epidermal growth factor (EGF) 8-13 and Jagged1 C2-EGF3 activation sites, as well as to two additional Jagged1 regions, EGF 8-11 and cysteine-rich domain (CRD). XL-MS and quantitative interaction experiments show that the three Notch1 binding sites on Jagged1 also engage intramolecularly.These interactions, together with Notch1 and Jagged1 ectodomain dimensions and flexibility determined by small-angle X-ray scattering (SAXS), support the formation of backfolded architectures.
    [Show full text]